Lifeboat Foundation

Interventions that may slow ageing include drugs (e.g., rapamycin, metformin), supplements (e.g., nicotinamide riboside, nicotinamide mononucleotide), lifestyle interventions (e.g., exercise) and diets (e.g., fasting)

Thanks to advances in modern medicine over the past century, the world’s population has experienced a marked increase in longevity. However, disparities exist that lead to groups with both shorter lifespan and significantly diminished health, especially in the aged. Unequal access to proper nutrition, healthcare services, and information to make informed health and nutrition decisions all contribute to these concerns. This in turn has hastened the ageing process in some and adversely affected others’ ability to age healthfully. Many in developing as well as developed societies are plagued with the dichotomy of simultaneous calorie excess and nutrient inadequacy. This has resulted in mental and physical deterioration, increased non-communicable disease rates, lost productivity and quality of life, and increased medical costs. While adequate nutrition is fundamental to good health, it remains unclear what impact various dietary interventions may have on improving healthspan and quality of life with age. With a rapidly ageing global population, there is an urgent need for innovative approaches to health promotion as individual’s age. Successful research, education, and interventions should include the development of both qualitative and quantitative biomarkers and other tools which can measure improvements in physiological integrity throughout life. Data-driven health policy shifts should be aimed at reducing the socio-economic inequalities that lead to premature ageing. A framework for progress has been proposed and published by the World Health Organization in its Global Strategy and Action Plan on Ageing and Health. This symposium focused on the impact of nutrition on this framework, stressing the need to better understand an individual’s balance of intrinsic capacity and functional abilities at various life stages, and the impact this balance has on their mental and physical health in the environments they inhabit.

Whooping cough has made an astonishing comeback, with 2012 seeing nearly 50,000 infections in the U.S. (the most since 1955), and a death rate in infants three times that of the rest of the population. The dramatic resurgence has puzzled public health officials, who have pointed to the waning effectiveness of the current vaccine and growing anti-vaccine sentiment as the most likely culprits.

But that might not be the whole story, suggests a new study published in BMC Medicine by Santa Fe Institute Omidyar Fellows Ben Althouse and Sam Scarpino. Their research points to a different, but related, source of the outbreak — vaccinated people who are infectious but who do not display the symptoms of whooping cough, suggesting that the number of people transmitting without symptoms may be many times greater than those transmitting with symptoms.

In the 1950s, highly successful vaccines based on inactivated pertussis cells (the bacteria that causes whooping cough) drove infection rates in the U.S. below one case per 100,000 people. But adverse side effects of those vaccines led to the development and introduction in the 1990s of acellular pertussis vaccines, which use just a handful of the bacteria’s proteins and bypass most of the side effects. (Currently given to children as part of the Tdap vaccine.)

Circa 2013

These patents form part of Regeneron’s global patent portfolio, which together protect fundamental inventions behind Regeneron’s VelocImmune humanized mice. The two patents listed above specifically contain claims covering genetically modified mice that have unrearranged human immunoglobulin variable region gene segments at endogenous mouse immunoglobulin loci. The VelocImmune mice contain the full repertoire of human heavy chain immunoglobulin genes and kappa light chain genes, each linked to endogenous mouse constant regions. As a result, VelocImmune mice generate a normal and robust immune response which many believe is becoming the gold standard for making human antibody therapeutics. VelocImmune is also proving to be one of the most valuable technologies in biotechnology history, in terms of the licensing and collaboration revenues it has helped generate.

TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Patent and Trademark Office granted U.S. Patent No. 8,502,018 relating to methods of genetically modifying a mouse to make human antibodies. A similar European.

Can you be reinfected with Covid-19?

I’m skeptical as to whether reinfection is possible or not from Covid-19. However studies have shown that the virus lasts longer than 2 weeks within the human body:

10 days: https://doi.org/10.1101/2020.03.05.

More than 2 weeks: https://jamanetwork.com/journals/jama/fullarticle/2762452

Continue reading “Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster” »

“Our hope is that the unique mechanism of action of Opaganib, with both anti-viral and anti-inflammatory activity, will help COVID-19 patients by reducing lung inflammation, and thus preventing the disease from progressing to a stage which requires mechanical ventilation,” said Mark L. Levitt, RedHill’s medical director.

Inadequate ventilator settings may cause overwhelming inflammatory responses associated with ventilator-induced lung injury (VILI) in patients with acute respiratory distress syndrome (ARDS). Here, we examined potential benefits of glutamine (GLN) on a two-hit model for VILI after acid aspiration-induced lung injury in rats. Rats were intratracheally challenged with hydrochloric acid as a first hit to induce lung inflammation, then randomly received intravenous GLN or lactated Ringer’s solution (vehicle control) thirty min before different ventilator strategies. Rats were then randomized to receive mechanical ventilation as a second hit with a high tidal volume (TV) of 15 mL/kg and zero positive end-expiratory pressure (PEEP) or a low TV of 6 mL/kg with PEEP of 5 cm H₂O. We evaluated lung oxygenation, inflammation, mechanics, and histology. After ventilator use for 4 h, high TV resulted in greater lung injury physiologic and biologic indices. Compared with vehicle treated rats, GLN administration attenuated lung injury, with improved oxygenation and static compliance, and decreased respiratory elastance, lung edema, extended lung destruction (lung injury scores and lung histology), neutrophil recruitment in the lung, and cytokine production. Thus, GLN administration improved the physiologic and biologic profiles of this experimental model of VILI based on the two-hit theory.

Keywords: acid aspiration, ARDS, glutamine, ventilator-induced lung injury.

Acute respiratory distress syndrome (ARDS) is a catastrophic syndrome among critically ill patients. One of its major causes is acid aspiration as an initial pneumonitis that may be complicated by subsequent bacterial pneumonia after inhaling low pH gastric fluid [1, 2, 3, 4]. Gastric fluid aspiration frequently occurs in trauma or critical patients with head trauma, alcohol or cerebrovascular accidents, and is also a complication of general anesthesia that occurs in 1 in 2000–3000 cases when anesthetics are used [3, 4].

Okay now I agree that Hyroxychloroquine works. Ventilators have a mortality rate of 80% yet people keep trashing this drug, while people like that French doctor say it works.

Doctors at nursing home: “It’s actually going well. People are getting better,” Armstrong told NPR, adding that after just a handful of days, some of the 39 patients on the medication are showing signs of improvement.”

“Paid Professionals:

Continue reading “COVID-19 Patients Given Unproven Drug In Texas Nursing Home In ‘Disconcerting’ Move” »

Featured Image Source: NASA

NASA has been highly dependent on booking Russian spacecraft for almost a decade. Ever since the Space Shuttle fleet was grounded in 2011, the United States has not conducted manned flights to space. Amid the Coronavirus pandemic, a final Russian Soyuz rocket launched a NASA Astronaut for the last time to the International Space Station (ISS). On April 9, the Soyuz-2.1 rocket lifted off from the Baikonur Cosmodrome in Kazakhstan, Russia, at 4:05 a.m. Eastern time. Then the Soyuz MS-16 spacecraft was deployed into orbit about 9 minutes later. After a 6-hour trip, the spacecraft docked to the orbiting laboratory. Onboard the Soyuz spacecraft were American Astronaut Chris Cassidy, and Russian Cosmonauts Anatoly Ivanishin and Ivan Vagner. They all makeup Expedition 63, the crew will stay at the orbiting laboratory for 6 months. Due to the coronavirus, staff during the launch was limited in order to avoid spreading the COVID-19 respiratory illness. Governments from across the world have issued ‘stay at home’ orders to avoid straining healthcare systems. NASA and Roscosmos took extra precautions by limiting contact with Astronauts so they would not take any illnesses to ISS. “I knew I was going to be in quarantine these two weeks, but what’s really different is everybody else around us is in quarantine, too,” Cassidy said in a prelaunch interview on NASA TV. “It’ll be a really, really skeletal crew in the Baikonur Cosmodrome, which will be quite different.”

After the successful Soyuz launch, NASA Administrator Jim Bridenstine stated:

Medical researchers have been studying everything we know about Covid-19. What have they learned – and is it enough to halt the pandemic?